What is the recommended treatment for a patient with an uncomplicated urinary tract infection caused by E. coli that is resistant to ciprofloxacin (a fluoroquinolone) but susceptible to Macrobid (nitrofurantoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Recommendation for Ciprofloxacin-Resistant, Nitrofurantoin-Susceptible UTI

Nitrofurantoin (Macrobid) 100 mg orally twice daily for 5-7 days is the recommended treatment for this uncomplicated urinary tract infection caused by E. coli resistant to ciprofloxacin but susceptible to nitrofurantoin. 1, 2

Primary Treatment Choice

  • Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily achieves clinical cure rates of 88-95% and bacteriologic cure rates of 86-92% for uncomplicated UTIs 1
  • The standard duration is 5-7 days for uncomplicated cystitis in women, with 5-day regimens showing equivalent efficacy to 7-day courses 1
  • Nitrofurantoin maintains excellent activity against E. coli with resistance rates of only 2.3%, even among isolates resistant to other agents 3

Why Nitrofurantoin Over Other Options

  • Among TMP-SMX-resistant E. coli isolates, only 1.9% show resistance to nitrofurantoin, compared to 9.5% resistant to ciprofloxacin 4
  • Nitrofurantoin demonstrates 95.6% susceptibility rates against E. coli uropathogens, making it superior to fluoroquinolones (75.6% susceptibility) and TMP-SMX (71% susceptibility) 3
  • Current IDSA guidelines recommend reserving fluoroquinolones as alternative agents only when other antimicrobials cannot be used, due to resistance promotion and collateral damage to normal flora 2

Clinical Efficacy Evidence

  • Head-to-head trials show nitrofurantoin achieves early clinical cure rates of 90-95%, comparable to ciprofloxacin (95%) and TMP-SMX (95%) 1
  • Late clinical cure rates (4-6 weeks post-treatment) remain high at 84-93% 1
  • A 3-day regimen of nitrofurantoin macrocrystals 100 mg four times daily achieved 88% clinical cure and 74% bacteriologic cure, significantly superior to placebo 1

Critical Prescribing Caveats

  • Do not use nitrofurantoin for pyelonephritis or complicated UTI - it achieves inadequate tissue concentrations outside the urinary tract 1
  • Nitrofurantoin is contraindicated in patients with creatinine clearance <30 mL/min due to inadequate urinary drug concentrations 1
  • The twice-daily monohydrate/macrocrystal formulation (Macrobid) is preferred over the four-times-daily macrocrystal formulation for improved adherence 1

Alternative Considerations if Nitrofurantoin Cannot Be Used

  • Fosfomycin 3 g single oral dose achieves 90-94% clinical cure rates and represents a reasonable alternative 1
  • For VRE-related uncomplicated UTI (less common scenario), fosfomycin or high-dose ampicillin (18-30 g IV daily) are options, though this is not the typical E. coli scenario 1
  • Avoid empiric use of any fluoroquinolone given documented resistance and guideline recommendations to reserve these agents 2, 5

Duration and Follow-Up

  • 5-7 days of nitrofurantoin is sufficient for uncomplicated cystitis in women 1
  • Consider 7-day duration if symptoms are severe or if there are minor complicating factors 1
  • No routine post-treatment urine culture is needed if symptoms resolve completely 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Ciprofloxacin Dosing for Uncomplicated UTI in Females

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.